Gilles Gallant

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Junji Tsurutani, Hiroji Iwata, Ian E. Krop et al. · Cancer Discovery · 2020 · 353 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer

U. Gatzemeier, Joachim von Pawel, Maya Gottfried et al. · Journal of Clinical Oncology · 2000 · 228 citations

Medicine, Oncology, Pharmacology +10

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

F. Anthony Greco, Philip Bonomi, Jeffrey Crawford et al. · Lung Cancer · 2008 · 164 citations

Medicine, Oncology, Pharmacology +17

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice

Robert J. Melder, Blaire L. Osborn, Todd Riccobene et al. · Cancer Immunology Immunotherapy · 2004 · 112 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +11

Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.

Zev A. Wainberg, Saeed Rafii, Ramesh K. Ramanathan et al. · Journal of Clinical Oncology · 2014 · 37 citations

Medicine, Oncology, Pharmacology +16